Business
AstraZeneca, Daiichi Sankyo in $6B oncology deal – MarketWatch
AstraZeneca PLC said Monday that it has entered into an oncology collaboration with Daiichi Sankyo Co. worth up to $6 billion that it said could redefine treatment standards in lung, breast and multiple other cancers.
The British pharmaceutical giant said it and Daiichi Sankyo will jointly develop and commercialize a new antibody drug conjugate, DS-1062, world-wide, except in Japan. The drug is currently in development, AstraZeneca said.
Under the collaboration, AstraZeneca will pay Daiichi Sa…
-
Noosa News21 hours agoTributes for woman allegedly mowed down on footpath in Maroochydore; Guilherme Dal Bo charged
-
General14 hours agoTwo people arrested after man fatally shot at McLaren Flat
-
General18 hours agoMan refused bail charged with depicting Adolf Hitler and Nazi symbols on boat
-
General7 hours agoThe one tweak that could grow your super by $200,000